Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?

Introduction: The management of antithrombotic therapy after intracerebral hemorrhage (ICH) in anticoagulated patients is not well defined. We analyzed the risks and benefits of antiplatelet therapy (AG) against the resumption of anticoagulation with vitamin K antagonists (AVK) in a series of patien...

Full description

Bibliographic Details
Authors: Vidal-Jordanaa, A; Barroeta-Espar, I; Pelayo, MPS; Mateo, J; Delgado-Mederos, R; Marti-Fabregas, J
Format: Article
Status:Published version
Publication date:2012
Country:España
Institution:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repository:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p11441
Online Access:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11441
Access Level:Open access
Keyword:Cerebral hemorrhage
Anticoagulation
Vitamin K antagonists
Antiplatelet treatment
_version_ 1878739093027815424
author Vidal-Jordanaa, A
author2 Barroeta-Espar, I
Pelayo, MPS
Mateo, J
Delgado-Mederos, R
Marti-Fabregas, J
author2_role author
author
author
author
author
author_browse Barroeta-Espar, I
Delgado-Mederos, R
Marti-Fabregas, J
Mateo, J
Pelayo, MPS
Vidal-Jordanaa, A
author_facet Vidal-Jordanaa, A
Barroeta-Espar, I
Pelayo, MPS
Mateo, J
Delgado-Mederos, R
Marti-Fabregas, J
author_role author
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
description Introduction: The management of antithrombotic therapy after intracerebral hemorrhage (ICH) in anticoagulated patients is not well defined. We analyzed the risks and benefits of antiplatelet therapy (AG) against the resumption of anticoagulation with vitamin K antagonists (AVK) in a series of patients. Material and methods: Retrospective study of ICH in anticoagulated patients. We registered demographic data, history of hypertension (HT), time of follow-up and new cerebral vascular events (ICH, stroke [IC]). Results: We evaluated 88 patients, mean age 69 +/- 9 years, 50% men, 73% hypertensive. During the acute phase 18 patients died and the follow-up was lost in 31. Of the remaining (n = 39), AVKs were resumed in 25 and changed to AG in 14. Comparing the characteristics of both groups, the anticoagulated group was younger (P = .005) and the embolic sources were more often of higher risk (P = .003). After an average follow-up of 54 +/- 31 months, the distribution of events was: IC (AVKs 8%, AG 14.3%, P = .6), ICH (AVKs 24%, AG 7.1%, P = .38), IC or ICH (AVKs 32%, AG 21.4%, P = .48) and death (AVKs 29%, AG 7.1%, P = .21). This trend of increased risk of new events in patients with AVKs was confirmed by Kaplan-Meier curves, although without statistical differences. Conclusions: Restarting AVK treatment after ICH in anticoagulated patients could increase the risk of new bleeding events and mortality. Prospective studies are needed to define a better and appropriate antithrombotic therapy after ICH related with anticoagulation. (C) 2011 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L. All rights reserved.
eu_rights_str_mv openAccess
format article
id ES_baeef5e7f3cd38eaa99ba9eb5fa65257
institution Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
network_acronym_str ES
network_name_str España
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p11441
publishDate 2012
publishDateSort 2012
publisher ELSEVIER ESPANA SLU
publisherStr ELSEVIER ESPANA SLU
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
spelling Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards? Vidal-Jordanaa, A Barroeta-Espar, I Pelayo, MPS Mateo, J Delgado-Mederos, R Marti-Fabregas, J Cerebral hemorrhage Anticoagulation Vitamin K antagonists Antiplatelet treatment Introduction: The management of antithrombotic therapy after intracerebral hemorrhage (ICH) in anticoagulated patients is not well defined. We analyzed the risks and benefits of antiplatelet therapy (AG) against the resumption of anticoagulation with vitamin K antagonists (AVK) in a series of patients. Material and methods: Retrospective study of ICH in anticoagulated patients. We registered demographic data, history of hypertension (HT), time of follow-up and new cerebral vascular events (ICH, stroke [IC]). Results: We evaluated 88 patients, mean age 69 +/- 9 years, 50% men, 73% hypertensive. During the acute phase 18 patients died and the follow-up was lost in 31. Of the remaining (n = 39), AVKs were resumed in 25 and changed to AG in 14. Comparing the characteristics of both groups, the anticoagulated group was younger (P = .005) and the embolic sources were more often of higher risk (P = .003). After an average follow-up of 54 +/- 31 months, the distribution of events was: IC (AVKs 8%, AG 14.3%, P = .6), ICH (AVKs 24%, AG 7.1%, P = .38), IC or ICH (AVKs 32%, AG 21.4%, P = .48) and death (AVKs 29%, AG 7.1%, P = .21). This trend of increased risk of new events in patients with AVKs was confirmed by Kaplan-Meier curves, although without statistical differences. Conclusions: Restarting AVK treatment after ICH in anticoagulated patients could increase the risk of new bleeding events and mortality. Prospective studies are needed to define a better and appropriate antithrombotic therapy after ICH related with anticoagulation. (C) 2011 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L. All rights reserved. ELSEVIER ESPANA SLU https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11441
spellingShingle Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?
Vidal-Jordanaa, A
Cerebral hemorrhage
Anticoagulation
Vitamin K antagonists
Antiplatelet treatment
status_str publishedVersion
title Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?
title_full Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?
title_fullStr Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?
title_full_unstemmed Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?
title_short Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?
title_sort Intracerebral hemorrhage in anticoagulated patients: What do we do afterwards?
topic Cerebral hemorrhage
Anticoagulation
Vitamin K antagonists
Antiplatelet treatment
topic_facet Cerebral hemorrhage
Anticoagulation
Vitamin K antagonists
Antiplatelet treatment
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11441